Phosphate handling as a determinant of osteoporosis in primary hyperparathyroidism

磷酸盐处理是原发性甲状旁腺功能亢进症骨质疏松症的决定因素

阅读:1

Abstract

INTRODUCTION: Primary hyperparathyroidism is characterized by chronic parathyroid hormone excess, leading to hypercalcemia, increased bone turnover, and skeletal complications. Although osteoporosis is a common manifestation of these, the biochemical determinants of bone loss remain insufficiently defined. The roles of active vitamin D and renal phosphate handling require further clarification. This study aimed to identify biochemical determinants of osteoporosis in patients with primary hyperparathyroidism, with a particular focus on the contribution of calcitriol levels and renal phosphate handling. We further sought to evaluate their predictive performance in discriminating osteoporotic from non-osteoporotic individuals. MATERIALS AND METHODS: We retrospectively analyzed 74 adults with primary hyperparathyroidism ineligible for surgery, assessing serum calcium, phosphate, vitamin D metabolites, parathormone, and 24 h urinary calcium. Renal phosphate handling was estimated by TMP/GFR. Logistic regression and ROC analyses identified independent predictors and optimal cutoff values for osteoporosis. RESULTS: Osteoporosis was present in 33.8% of patients. Individuals with osteoporosis demonstrated significantly higher calcitriol levels and lower renal phosphate reabsorption, also in multivariate analysis, while serum calcium, phosphate, and 25-hydroxyvitamin D did not differ between groups. Receiver operating characteristic curve analysis identified clinically meaningful cutoff values for both parameters. CONCLUSION: Increased levels of the active form of vitamin D and impaired renal conservation of phosphate are independently associated with osteoporosis in primary hyperparathyroidism, outperforming traditional biochemical markers. Incorporating these measures into routine clinical assessment may improve identification of patients at high skeletal risk and enhance decision-making in the management of bone disease in primary hyperparathyroidism.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。